P-PSMA-101 CAR-T Cells for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a treatment where a patient's immune cells are modified to better fight advanced prostate and salivary gland cancers. The modified cells are reintroduced into the body to target and destroy cancer cells.
Will I have to stop taking my current medications?
The trial requires that you stop taking anti-cancer medications (except GnRH targeted therapies) and immunosuppressive medications at least 2 weeks before starting certain parts of the study. You should discuss your specific medications with the trial team to understand how they might be affected.
Is P-PSMA-101 CAR-T cell therapy safe for humans?
Early studies on PSMA-targeting CAR T cells, including those with a dominant-negative TGFβ receptor, show that they are generally safe and feasible for treating prostate cancer. However, challenges such as dose-limiting toxicity and immune-related side effects have been noted in clinical trials.12345
How is the P-PSMA-101 CAR-T cell treatment different from other prostate cancer treatments?
P-PSMA-101 CAR-T cells are unique because they are engineered to specifically target the prostate-specific membrane antigen (PSMA) on prostate cancer cells, potentially offering a more precise attack on the cancer compared to traditional treatments. This approach uses the patient's own immune cells, which are modified to better recognize and destroy cancer cells, and represents a novel strategy in treating prostate cancer, especially in cases where other treatments have failed.12367
What data supports the effectiveness of the treatment P-PSMA-101 CAR-T cells for prostate cancer?
Research shows that CAR-T cell therapy, which involves modifying a patient's immune cells to target cancer cells, has shown promise in treating prostate cancer by specifically targeting the prostate-specific membrane antigen (PSMA) found on cancer cells. Early clinical studies have demonstrated antitumor activity, suggesting potential effectiveness in prostate cancer treatment.12368
Who Is on the Research Team?
Rajesh Belani, M.D.
Principal Investigator
Sponsor Executive Medical Director
Are You a Good Fit for This Trial?
This trial is for adults over 18 with advanced prostate cancer (mCRPC) or salivary gland cancers (SGC). Participants should be relatively healthy, able to perform daily activities with ease or minor difficulty (ECOG status of 0-1), and have organs functioning within certain limits. Men must agree to use birth control during the study and for two years after.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Leukapheresis and Manufacturing
Participants undergo leukapheresis to collect PBMCs, which are sent for manufacturing of P-PSMA-101 CAR-T cells
Treatment
Participants receive P-PSMA-101 CAR-T cells following a lymphodepleting chemotherapy regimen
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- P-PSMA-101 CAR-T cells
- Rimiducid
Find a Clinic Near You
Who Is Running the Clinical Trial?
Poseida Therapeutics, Inc.
Lead Sponsor